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with short course hypofractionated radiotherapy (RT) were included in 
this study. Pre-operative treatment with RT was followed by a total 
mesorectal excision (TME) within 3 days after the last RT fraction. For 
each patient, a FDG-PET-CT scan was performed prior to the start of 
treatment. The tumor was automatically delineated from the PET-
images using SUV-thresholding, with the threshold depending on the 
tumor-to-background signal ratio. The volume of the PET-based tumor 
contour was validated by pathological examination of the resected 
specimen. For this validation, the resected specimen was sliced into 5 
mm slices and each slice was photographed. On the photographs, the 
tumor was manually delineated by the pathologist. The tumor volume 
was calculated by multiplying the tumors surface area with the slice 
thickness of 5 mm. Automatic delineation with other methods, 
including watershed based clustering, will be presented. 
Results: Automatic SUV-threshold based tumor delineation resulted in 
an average tumor volume of 16.2±11.3 cm3 (range: 7.7 to 38.7 cm3), 
whereas pathological examination of the resected specimens resulted 
in an average tumor volume of 16.0±11.5 cm3 (range: 7.8 to 36.5 cm3). 
The average volume difference was 2±2.0 cm3 (range: -2.2 to 3.0 
cm3). A correlation coefficient of 0.964 (p<0.001) was found when 
correlating the tumor volumes resulting from PET-analysis and 
pathological examination. 
Conclusions: The strong correlation between the tumor volumes 
resulting from SUV-thresholding of PET-images and pathological 
examination of the surgical specimen demonstrates the accuracy of 
automatic PET-based tumor delineation based on SUV-thresholding for 
patients diagnosed with rectal cancer. This unique 3D dataset will be 
used as golden standard for the comparison of multiple PET-based 
automatic segmentation algorithms. 
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Purpose/Objective: The clinical utility of alpha-fetoprotein (AFP) as a 
predictor of treatment outcome in patients with advanced HCC 
receiving stereotactic body radiotherapy (SBRT) has been poorly 
defined. We aimed to study the clinical value of AFP response in an 
attempt to validate it as a surrogate serologic end point. 
Materials and Methods: We analyzed the prospectively collected data 
of 53 locally advanced HCC patients with elevation of AFP (>20) 
received individualized hypofractionated radiotherapy using 
stereotactic body radiotherapy (SBRT) technique between 2006 and 
2011. AFP response defined as >50% decrease from baseline, 3 months 
after the completion of SBRT. Radiological response rate was assessed 
by CT scan using RECIST criteria.  
Results: Median follow-up time was 11.2 months. Patients' 
characteristics were as follows: Median age (62 years, range: 36-86); 
Male/ female (n= 44/9 respectively); Child-Pugh class A/B (n= 45/8 
respectively); and portal vein thrombosis (n=23). Individualized 
hypofractionated radiotherapy using SBRT technique was given at 4Gy 
per fraction, range from 5-10 fractions, with the median dose of 32Gy 
was delivered. The overall response rate was 39.6%. The median 
overall survival (OS) and progression free survival (PFS) was 11.2 
months and 5.4 months respectively. AFP responders (n= 22) had 
better objective response rate than AFP non-responders (n=31) after 
SBRT (59.1 vs. 25.8%; P=0.01). Median OS rate was longer in AFP 
responders (17.9 vs 9.0 months, p=0.02). Median PFS rate was also 
longer in AFP responder than AFP non-responders although it was not 
statistically significant. (PFS, 7.0 vs 5.1 months, p= 0.18). In 
multivariate analysis, AFP response was independent factor affecting 
OS (hazard ratio, 2.46; 95% CI, 1.07 to 5.68; p=0.035). Of the 29 
patients with radiological stable disease (SD), AFP responders (n=9) 
had a better 1-year survival rate than AFP non-responders (n=20) 
(66.7% vs 31.9%, p=0.049). 
Figure 1. Overall survival (OS) of AFP responders and AFP non-
responders 
 
Conclusions: AFP response is useful in predicting prognosis and 
treatment response in patients with advanced HCC received SBRT. 
Incorporation of AFP response into the criteria of evaluating the 
outcome of SBRT should be considered. Additional treatment may 
require in the AFP non-responders. 
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Purpose/Objective: To investigate the possible benefit deriving from 
whole pelvis radiotherapy (WPRT) in combination with high-dose 
salvage radiotherapy (HDSRT) in the salvage treatment of node-
negative patients experiencing a biochemical recurrence (BR) after 
radical prostatectomy (RP) and pelvic lymphoadenectomy. 
Materials and Methods: From 1998 to 2008, 208 node-negative 
(median 11 LN) patients (pts) underwent HDSRT at 1.8 Gy/fraction to 
the prostatic bed (PB) only (n=138, median dose 73.8 Gy) or to WPRT 
(n=70, median dose 50.4 Gy) followed by a boost to PB (median dose 
75.6 Gy). All pts underwent 3DCRT technique except for 28 who 
received WPRT-IMRT followed by a 3DCRT boost to PB. 
Patients characteristics were comparable in terms of preoperative 
PSA, pT, surgical margins, Gleason score (GS), median time to BR 
after RP (overall 21.5 months), median PSA doubling time (PSADT, 
overall 8.9 months), PSA at SRT (PSA@SRT, overall 0.70 ng/mL) and 
fraction of pts receiving neoadjuvant (NAD) or adjuvant androgen 
deprivation (AAD) in addition to SRT. The 2 groups differed 
significantly in terms of median follow-up (FU, 102 vs 73 months, 
owing to the gradual introduction of WPRT over time), fraction of 
biopsy confirmed local relapse (49% vs 31%), length of AAD (10 vs 15 
months) and median RT dose (73.8 vs 75.6 Gy) in PB vs WPRT+PB 
group, respectively.  
Results: After a median FU of 87 months, WPRT+PB resulted in a 
significant improvement of 7-year biochemical relapse-free survival 
(bRFS) when compared to PB only both in the overall population (86 vs 
67%, p=0.02) and in the subset of the 134 pts with a PSA@SRT ≤1 
ng/mL (90 vs 69%, p=0.02). The other factor predictive of improved 
bRFS at univariate analysis (UA) in both subgroups was RT dose (p-
value always <0.0001, most informative cut-off <73.8 Gy in both 
cohorts). Radiation doses ≥75.6 Gy resulted in improved 7-year bRFS 
both in the overall population (87% vs 63%, p<0.0001) and in pts with 
PSA@SRT ≤1 ng/mL (85% vs 65%, p=0.002). In the overall population, 
pT and PSADT (but not NAD nor AAD) were also significant predictors 
of bRFS at UA. At multivariate analysis, in the overall population 
PSA@SRT, RT dose ≤73.8 Gy, PB only irradiation and GS 7-10 (and in 
the subset with PSA@SRT ≤1 ng/mL, PB only RT and and GS ≥8) 
independently predicted treatment failure. Overall, HDSRT resulted in 
only mild acute and late genitourinary (GU) and gastrointestinal (GI) 
toxicity (TOX), without significant differences between WPRT+PB or 
PB subgroups. Of note, WPRT resulted in a doubling of acute intestinal 
G2 TOX (15 vs 7%), a finding which disappeared when only pts treated 
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with IMRT were considered (incidence 7%). Late G2 and G3 GU TOX 
were 6% vs 7% and 3% vs 3%, respectively. 
Conclusions: This study provides support for the use of WPRT in 
combination with HDSRT in the salvage setting in node-negative 
patients. Especially if delivered with modern IMRT techniques, WPRT 
did not result in any additional toxicity. 
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Purpose/Objective: Numerous authors have attempted to establish 
models to minimise rectal late effects following prostate 
radiotherapy, most using data from standard fractionation regimes 
with disagreement as to predictive dosimetric values. This study 
looked to identify predictive Biochemical Equivalent Dose (BED) 
volumes, applicable for any treatment regime, using various dose 
mapping techniques. 
Materials and Methods: We retrospectively analysed dose volume 
data for 172 prostate adenocarcinoma patients, median age 65.1 
(range 48.1-75.5), treated at a single centre between 2006 and 2009 
with radical radiotherapy. All patients received 3D_CRT or IMRT 
according to evolving practise with dose fractions as shown in the 
table.  
 
Fractionation 52.5Gy/20# 50Gy/16# 74Gy/37# 60Gy/20# 57Gy/19# 
Planning 3D-CRT 3D-CRT IMRT IMRT IMRT 
Number 11 64 9 7 81 
 
Rectal dose-volume histograms (DVH) and dose-surface histograms 
(DVS) were calculated for each patient using standard rectal 
contouring (ano-rectal to recto-sigmoid junction) all performed or 
reviewed by the author. In addition distribution of dose to the latitude 
of the rectum was examined by converting the rectal surface dose 
into a 2D structure. Dose was converted into a BED using an 
alpha/beta ratio of 3 for the rectum. 
Each patient completed a LENT-SOMA questionnaire to assess late 
rectal toxicity. For this study answers regarding issue with 
constipation or diarrhoea were not considered as this was not felt to 
represent true late rectal toxicity alone. Partition analysis was 
performed for all data and for IMRT alone to establish if there was a 
BED and volume for any given mapping technique that was statistically 
significant in predicting late rectal toxicity (score ≥2).  
Results: Partition analysis from 0-100% of volume was performed at 
BED levels of 120Gy, 110Gy, 100Gy, 90Gy, 80Gy, 70Gy and 60Gy. At all 
of these doses there was no percentage volume of rectum receiving a 
given dose that was predictive for the development of late rectal 
toxicity regardless of dose mapping method and radiotherapy 
technique used.  
Conclusions: This study does not support the hypothesis that 
incidence of toxicity significantly increases above threshold 
dose/volumes using BED. This conflicts with previous studies looking 
at dose volume in standard 2Gy per fraction and others looking at the 
use of Equivalent Uniform Dose to normalise data from varying 
fractionation regimes. The use of lateral dose distribution has not 
been shown to have any additional predictive power over conventional 
dose mapping. This may in part be due to unaccounted for movement 
of the rectum during treatment comprising dose mapping data. 
Further ongoing study is attempting to quantify this degree of intra-
treatment movement and will be reported when available. 
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Purpose/Objective: The aim of the present study was to investigate 
the diagnostic gain in the detection of lymph node (LN) metastases by 
means of immunohistochemical (IHC) staining for pankeratin as 
compared to the routine histopathological evaluation. In addition, E-
Cadherin (ECad) expression was investigated within the concept of 
epithelial mesenchymal plasticity. 
Materials and Methods: Forty patients with a risk ≥10% but <35% for 
LN metastases (Partin tables) who were N0 at contrast-enhanced CT-
scan and did not receive any prior treatment were included in the 
study. They all underwent a superextended LND followed by radical 
prostatectomy (RP). All LN (n=838) were completely serially sectioned 
at 300µm and stained for pankeratin (n=4498), in addition to one 
central H&E-stained section per LN. Disease positivity was defined as 
the presence of any metastatic deposits in a LN and classified as 
follows: Macro+ (> 2mm), micro+ (<2 mm but >0.2 mm) and ITC (< 
0.2mm). ECad staining was performed on the diagnostic biopsies 
(n=36), RP specimens (n=39) and on the pankeratin-positive LN 
sections. Staining intensity was scored as negative/weak (1), 
moderate (2) or strong (3) and the staining pattern as inhomgeneous 
(0) or homogeneous (1). In case of staining heterogeneity, the most 
prevalent staining intensity was scored (Table 1). 
Results: Sixteen out of 40 (40%) patients were found to be node-
positive (N1) after routine H&E analysis. More specifically, 44 (5.3%) 
affected LN were found in which 25 Macro+, 19 micro+ and 9 ITC were 
detected. Step-section IHC analysis with pankeratin revealed 
metastatic disease in 2 patients that were previously N0. In each of 
these patients 1 affected LN was found, i.e. 1 LN harbouring a micro+ 
as well as a group of ITC and the other one harbouring only 1 group of 
ITC. Four additional affected LN in which micro+ and/or ITC were 
detected, were found in 3 patients that were already N1. Altogether, 
this detailed IHC analysis resulted in 50 (6.0%) affected LN, i.e. 25 
Macro+, 24 micro+ and 17 groups of ITC, that were found in 18/40 
(45%) patients. The majority of biopsies (92%) and RP specimens (79%) 
showed strong, homogeneous ECad expression. In contrast, ECad 
expression in the LN was found to be weak in about 60% of all cases. 
While the ECad staining pattern in the ITC and micro+ was mainly 
homogenous, the Macro+ showed a much more heterogeneous pattern 
(Pearson Chi-square p <0.0001). 
 
 
Conclusions: IHC analysis of serially sectioned LN increased the 
detection rate of pelvic LN metastases only marginally. This labour-
intensive and expensive procedure cannot be recommended as long as 
the clinical relevance of micrometastatic disease and ITC is not 
proven. Indicative to this could be the difference in ECad staining 
homogeneity between the ITC/micro+ and Macro+. The different 
staining intensities in the Macro+ may indicate an ongoing 
mesenchymal epithelial transition, presumed to be a mechanism for 
metastatic colonisation [Wells A 2008].  
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Purpose/Objective: Whole-pelvis radiotherapy (WPRT) may have a 
role both in the adjuvant (ADV) and salvage (SALV) setting after 
radical prostatectomy (RP) for prostate cancer (PCa). Aim of this 
analysis was to investigate a possible role of WPRT in increasing the 
risk of radiation-induced second neoplasms (2ndNPL) in the post-
prostatectomy setting. 
